(Q37142052)

18 August 2017

1 reference

title

Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs (English)

1 reference

18 August 2017

0 references

0 references

1 reference

1 reference

J Avouac

1

0 references

author name string

Y Allanore

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

1121-1128

1 reference

Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

The role of endothelial cell dysfunction in the cardiovascular mortality of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Adipose tissue, inflammation, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Endothelial progenitor cells and rheumatic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Circulating endothelial progenitor cells and cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Stress-activated cytokines and the heart: from adaptation to maladaptation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

Effect of anti–tumor necrosis factor α therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1121

10.1517/14656566.9.7.1121

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference